These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 34050922)
1. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. Karkucinska-Wieckowska A; Simoes ICM; Kalinowski P; Lebiedzinska-Arciszewska M; Zieniewicz K; Milkiewicz P; Górska-Ponikowska M; Pinton P; Malik AN; Krawczyk M; Oliveira PJ; Wieckowski MR Eur J Clin Invest; 2022 Mar; 52(3):e13622. PubMed ID: 34050922 [TBL] [Abstract][Full Text] [Related]
2. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Tariq Z; Green CJ; Hodson L Liver Int; 2014 Aug; 34(7):e180-90. PubMed ID: 24621397 [TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Di Ciaula A; Passarella S; Shanmugam H; Noviello M; Bonfrate L; Wang DQ; Portincasa P Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065331 [TBL] [Abstract][Full Text] [Related]
4. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease. Paradies G; Paradies V; Ruggiero FM; Petrosillo G World J Gastroenterol; 2014 Oct; 20(39):14205-18. PubMed ID: 25339807 [TBL] [Abstract][Full Text] [Related]
5. From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria. Amorim R; Magalhães CC; Borges F; Oliveira PJ; Teixeira J Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106795 [TBL] [Abstract][Full Text] [Related]
6. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. Grattagliano I; Montezinho LP; Oliveira PJ; Frühbeck G; Gómez-Ambrosi J; Montecucco F; Carbone F; Wieckowski MR; Wang DQ; Portincasa P Biochem Pharmacol; 2019 Feb; 160():34-45. PubMed ID: 30508523 [TBL] [Abstract][Full Text] [Related]
7. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Spahis S; Delvin E; Borys JM; Levy E Antioxid Redox Signal; 2017 Apr; 26(10):519-541. PubMed ID: 27452109 [TBL] [Abstract][Full Text] [Related]
8. Changes in Key Mitochondrial Lipids Accompany Mitochondrial Dysfunction and Oxidative Stress in NAFLD. Durand M; Coué M; Croyal M; Moyon T; Tesse A; Atger F; Ouguerram K; Jacobi D Oxid Med Cell Longev; 2021; 2021():9986299. PubMed ID: 34257827 [TBL] [Abstract][Full Text] [Related]
9. The Alterations of Mitochondrial Function during NAFLD Progression-An Independent Effect of Mitochondrial ROS Production. Simões ICM; Amorim R; Teixeira J; Karkucinska-Wieckowska A; Carvalho A; Pereira SP; Simões RF; Szymanska S; Dąbrowski M; Janikiewicz J; Dobrzyń A; Oliveira PJ; Potes Y; Wieckowski MR Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202179 [TBL] [Abstract][Full Text] [Related]
10. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants. Rives C; Fougerat A; Ellero-Simatos S; Loiseau N; Guillou H; Gamet-Payrastre L; Wahli W Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371482 [TBL] [Abstract][Full Text] [Related]
11. Role of mitochondria in nonalcoholic fatty liver disease. Nassir F; Ibdah JA Int J Mol Sci; 2014 May; 15(5):8713-42. PubMed ID: 24837835 [TBL] [Abstract][Full Text] [Related]
12. The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis. Ucar F; Sezer S; Erdogan S; Akyol S; Armutcu F; Akyol O Redox Rep; 2013; 18(4):127-33. PubMed ID: 23743495 [TBL] [Abstract][Full Text] [Related]
13. Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction. Xu L; Nagata N; Ota T Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31775341 [TBL] [Abstract][Full Text] [Related]
16. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Chen G; Ni Y; Nagata N; Xu L; Ota T Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875 [TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction. Boland ML; Oldham S; Boland BB; Will S; Lapointe JM; Guionaud S; Rhodes CJ; Trevaskis JL World J Gastroenterol; 2018 Apr; 24(16):1748-1765. PubMed ID: 29713129 [TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Pafili K; Roden M Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492 [TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Pierantonelli I; Svegliati-Baroni G Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287 [TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]